NTRC-12026-0

N/A

Report date: 2023/10/12 16:24:32
NME

Base Information

Drug NameNTRC-12026-0
Drug Alias NameNTRC-12026-0
ClassificationOther
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCrossfire Oncology BV
China Registration ClassN/A

Develop Information

Active CompaniesCrossfire Oncology BV
Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A